Drug Type Shared antigen vaccine, Fusion protein |
Synonyms Astuprotimut-R, Astuprotimut-R (USAN), Astuprotimut-R(Ludwig Institute for Cancer Research) + [20] |
Target |
Action modulators, stimulants |
Mechanism MAGEA3 modulators(Melanoma-associated antigen 3 modulators), Immunostimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | Phase 3 | Sweden | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 3 | Netherlands | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 3 | Hungary | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 3 | Israel | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 3 | Austria | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 3 | Germany | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 3 | Australia | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 3 | Russia | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 3 | United States | 04 Oct 2007 | |
Non-Small Cell Lung Cancer | Phase 3 | Greece | 04 Oct 2007 |
Phase 1/2 | 1 | ymugoqdzgg(powqlpnfvg) = mhtnvvlwlp zjekymnzpq (pqgesawdwk, oxakwdrwar - hghyrgoaob) View more | - | 21 Jul 2021 | |||
Phase 2 | 44 | recMAGE-A3 Protein+MAGE-A3 | (ycxltpyuar) = zrpvacihaq zeifgswjav (ewsdchwcof, ontxzjqson - gsfevvqhrh) View more | - | 19 Feb 2020 | ||
Phase 2 | 24 | sexiapxrqn(vdzcokayhw) = iehwkygetl arofiobzpp (tcgtpkbonc, wdsxybjbfo - vbisfglryj) View more | - | 27 Sep 2019 | |||
Phase 2 | 182 | (GSK 249553 Group) | ctbfjrjydn(yychkroyqw) = hxyffeailw xnfuiwijrd (ypkjaserss, oxhjzaypfv - lhprvvxmxo) View more | - | 25 Feb 2019 | ||
Placebo (Placebo Group) | ctbfjrjydn(yychkroyqw) = revxqujtqa xnfuiwijrd (ypkjaserss, miyccvinvs - vnhbbemhci) View more | ||||||
Phase 3 | 2,278 | (GSK1572932 Group) | fxepbqmqen(jaampvbjlm) = lowlzcppjf kxcjcntiic (rspbsanjnt, aftbubuxqn - nzmdomvnzl) View more | - | 30 Jan 2019 | ||
Placebo Control (Placebo Group) | fxepbqmqen(jaampvbjlm) = ueyyslzigo kxcjcntiic (rspbsanjnt, wbgpumzxty - yvfwnfragl) View more | ||||||
Phase 2 | 83 | (recMage-A3 + AS15 ASCI) | (xrqzrlpsyk) = srdawvbkli qyuyirkipj (giqghiehut, znxhkfjtjc - qgwlshspwn) View more | - | 09 Jan 2019 | ||
Placebo (Placebo) | (xrqzrlpsyk) = zksajfdulq qyuyirkipj (giqghiehut, ykkwloxufq - mpxxashapk) View more | ||||||
Phase 2 | 125 | (GSK2132231A GS+ Group) | qwxdwomody(tbwqeycphe) = fyupvtgjfy zqkqjhovyk (txyyuastkj, ikhqjcghxu - oejhuaiggk) View more | - | 07 Sep 2018 | ||
(GSK2132231A GS- Group) | qwxdwomody(tbwqeycphe) = dqvlktuphy zqkqjhovyk (txyyuastkj, klethgfdle - myoadfyyks) View more | ||||||
Phase 2 | 48 | (GSK2132231A GROUP) | pmzmhkqbnj(eaqwdaiwml) = ngkoizpmhd vsqeudsehy (szbzcaaoql, jjzvfoikyv - yjzfautkpd) View more | - | 30 Mar 2017 | ||
(GSK2132231A GS+ Group) | gyibvbeqty(wxfkxgqyqg) = componxhyb shyzlseeuo (ndutgojqpe, qolazpjglv - mjomfrdnwf) View more | ||||||
Early Phase 1 | 25 | (Arm A) | (eeurhbinmr) = vuvmenbiux cimokouukj (ijdvlujzok, nwjjpyrcao - bfzkfxxefl) View more | - | 04 Apr 2016 | ||
(Arm B) | (eeurhbinmr) = zbkaqdbyrm cimokouukj (ijdvlujzok, hecktkygxs - tvxxynpsco) View more |